FDAnews Drug Daily Bulletin

AMGEN PRICES $5.0 BILLION CONVERTIBLE SENIOR NOTES

Feb. 16, 2006
A A

Biotechnology industry news provided by Financial News USA Amgen, the world's largest biotechnology company, recently announced the pricing of $2.5 billion principal amount of Convertible Senior Notes due 2011 and $2.5 billion principal amount of Convertible Senior Notes due 2013, for an aggregate transaction size of $5 billion.
Financial News USA